Channel Wealth LLC Purchases 23,711 Shares of AstraZeneca PLC (NASDAQ:AZN)

Channel Wealth LLC increased its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 144.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,175 shares of the company's stock after purchasing an additional 23,711 shares during the quarter. Channel Wealth LLC's holdings in AstraZeneca were worth $2,632,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of AZN. Stratos Wealth Advisors LLC lifted its position in shares of AstraZeneca by 2.0% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company's stock worth $522,000 after purchasing an additional 133 shares during the period. Crumly & Associates Inc. lifted its holdings in AstraZeneca by 2.2% in the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company's stock worth $518,000 after buying an additional 143 shares during the period. Harbour Investments Inc. lifted its holdings in AstraZeneca by 1.9% in the third quarter. Harbour Investments Inc. now owns 8,805 shares of the company's stock worth $686,000 after buying an additional 160 shares during the period. Smith Salley Wealth Management boosted its position in AstraZeneca by 1.0% during the 3rd quarter. Smith Salley Wealth Management now owns 16,158 shares of the company's stock valued at $1,259,000 after acquiring an additional 162 shares in the last quarter. Finally, Veracity Capital LLC grew its holdings in shares of AstraZeneca by 4.5% during the 3rd quarter. Veracity Capital LLC now owns 3,833 shares of the company's stock worth $299,000 after acquiring an additional 164 shares during the period. Hedge funds and other institutional investors own 20.35% of the company's stock.

AstraZeneca Stock Down 0.4 %

Shares of NASDAQ:AZN traded down $0.29 on Friday, hitting $66.62. 4,061,562 shares of the company traded hands, compared to its average volume of 4,791,265. The stock has a 50 day simple moving average of $66.06 and a 200-day simple moving average of $74.57. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The company has a market cap of $206.57 billion, a PE ratio of 31.88, a PEG ratio of 1.05 and a beta of 0.46. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. The firm had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business's revenue was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.87 earnings per share. As a group, research analysts expect that AstraZeneca PLC will post 4.11 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on AZN shares. UBS Group upgraded AstraZeneca from a "sell" rating to a "neutral" rating in a research note on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a "sell" rating to a "hold" rating in a report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $89.75.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.